Phase II Trial Of Oxaliplatin With Docetaxel Followed By Epidermal Growth Factor Antibody (EGFR-AB) Cetuximab In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
This is a non-randomized, open-label, phase II study to assess the effects of oxaliplatin
and docetaxel followed by epidermal factor-antibody (EGFR-AB) cetuximab on patients with
previously treated recurrent /metastatic squamous cell carcinoma of the head and neck.
Head and neck tissue will also be tested to determine if the protein Epidermal Growth Factor
Receptor is present in the cancer cells.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate as determined by RECIST criteria (CR and PR) will be used to determine efficacy in terms of reduction of tumor size and control of disease
12 Weeks, 1 Year
Chao Huang, MD
University of Kansas
United States: Food and Drug Administration
|University of Kansas Medical Center||Kansas City, Kansas 66160-7353|